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Impact Of Intraaortic Balloon Pump On 30-Day Mortality In Cardiogenic Shock
AMI Patients With Unsuccessful And Successful Primary PCI - Analysis From
PL-ACS Registry
Mariusz Gasior1, Marek Gierlotka1, Michal Hawranek1, Damian Pres1,
Wiktor Kuliczkowski1, Piotr Knapik1, Zbigniew Kalarus1, Marian Zembala1,
Lech Polonski1
1Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland
Background: Recently, usefulness of intraaortic balloon pump (IABP) for patients
with acute myocardial infarction (AMI) and cardiogenic shock (CS) is questioned.
Therefore we analysed inﬂuence of IABP in CS AMI patients with unsuccessful and
successful primary PCI on 30-day mortality.
Methods: We analysed 4211 patients with CS and AMI from nationwide PL-ACS
registry. Unsuccessful PCI was deﬁned as ﬁnal TIMI ﬂow grade 0 or 1.
Results: Patients with unsuccessful PCI comprised 13.5% (table). In both unsuc-
cessful and successful PCI groups 20% of patients had IABP support and these
patients were of the higher risk proﬁle. IABP was associated with lower 30-day
mortality in unsuccessful PCI group while with higher in successful PCI group. After
adjustment in multivariate Cox proportional model regression IABP remained
signiﬁcantly associated with reduction of 30-day mortality in patients with unsuc-
cessful PCI (HR ¼ 0.71, 95%CI ¼ 0.55-0.91, p¼0.0065) and increased mortality in
patients with successful PCI (HR ¼ 1.26, 95%CI ¼ 1.13-1.43, p<0.0001).Unsuccessful PCI
(ﬁnal TIMI ﬂow 0 or 1)
N=569 (13.5%)
Successful PCI
(ﬁnal TIMI ﬂow 2 or 3)
N=3642 (86.5%)
No IABP IABP P value No IABP IABP P value
Number of patients, n (%) 457 (80%) 112 (20%) 2919 (80%) 723 (20%)
Mean age,
years  SD
70  12 67  11 0.0049 66  12 66  12 0.89
Female sex, % 43 38 0.71 36 33 0.24
Diabetes, % 29 41 0.015 26 31 0.0093
Prior myocardial
infarction, %
20 21 0.72 15 20 0.0004
Cardiac arrest before
admission, %
19 13 0.15 21 18 0.11
Systolic pressure on
admission, %
79  37 81  27 0.46 88  34 83  29 0.0003
Mean heart rate on
admission, %
89  33 88  28 0.89 83  31 91  30 <0.0001
STEMI, % 83 88 0.17 85 83 0.16
Left ventricle ejection
fraction, %
31  13 26  12 0.017 39  13 31  12 <0.0001
TIMI ﬂow 0 or 1
before PCI, %
96 100 0.078 83 86 0.056
Multivessel diseases, % 71 69 0.76 61 74 <0.0001
IIb/IIIa inhibitors, % 36 44 0.11 35 54 <0.0001
L
SConclusions: Use of IABP in patients with AMI and CS seems to be beneﬁcial when
primary PCI is unsuccessful but may be harmful when PCI is successful in restoring
patency of the infarct related artery.
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infarction (STEMI): Insights from Glenﬁeld-Leicester UK ACS registry.
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Background: The burden of cardiovascular disease is higher amongst Octogenarians
(OG). Increasing numbers of OGs are undergoing Primary Percutaneous Intervention
(PPCI) for ST elevation myocardial infarction (STEMI) against a background of
potential excess risks associated with the procedure. There is very limited long-term
outcome data available in this patient population.
Methods: Objective: To analyze one year all-cause mortality in OGs who were
admitted with a STEMI and received PPCI in a tertiary cardiac centre in the UK and to
observe the impact of vascular access (Femoral vs. Radial) on mortality. Design: The
registry records of 2951 consecutive STEMI patients, age >50 years admitted between
2005-2011 were reviewed at patient-level data. One year all-cause mortality data was
obtained from the national MINAP-UK data base and collated with local registry
information. Kaplan-Meier and Cox regression analysis were used to compare
mortality between OG and age-group 50-79 years.
Results: Of the total population, 8.1 % (n¼241, Mean age:85.3yrs (SD:3.4) were
OG of whom 53.5% were male. Use of heparin, warfarin, bivalirudin, aspirin, andJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrclopidogrel were comparable between groups. Use of femoral arterial access (63%)
was signiﬁcantly higher amongst OG (P¼0.04) compared to radial route. In univariate
analysis, event-free-survival (hazard ratio: 2.5 CI [1-6.1]) was signiﬁcantly lower in
OG compared to other age group (log rank test, P¼0.001). All-cause mortality was
signiﬁcantly higher amongst OG who had femoral arterial access compared to radial
route (log rank test, P¼0.03), but this was not apparent amongst 50-79 age group (log
rank, P¼0.06). In Cox regression analysis, after adjusting for gender, conventional
risk factors, anticoagulation and antiplatelet-use, femoral access remained signiﬁcantly
associated with one year all cause mortality (hazard ratio:2.8[1-7.3], P¼0.04).
Conclusions: OG who received PPCI for STEMI have disproportionately higher one
year all cause mortality compared to younger age group. Use of femoral arterial access
appears to be independently associatedwith this excessmortality. Radial access preferred
to be the safer option in this high risk population, to improve long term prognosis.
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Background: New-generation DES showed favourable outcomes in patients with
STEMI. We aim to assess mid- and long-term outcomes in STEMI patients treated
with Nobori, DES with bioresorbable polymer.
Methods: In 2 large, prospective, multi-center registries, out of 14134 enrolled
patients, 1302 patients with STEMI were treated with the Nobori DES. Mid-term and
long-term outcomes (up to 1 and 3 years) are available for 806 and 248 patients
respectively. Adverse events were adjudicated by CEC.
Results: STEMI patients were 6013y old, 79% males, 16% with prior MI and 10%
with prior coronary revascularizations. The pain-to-balloon time was <3 hours in
37.6%; >3 < 6 hours in 22.6%; > 6 < 12 hours in 12.8% and > 12 hours in 19.6% of
the patients. The median door-to-balloon time was 55 minutes. Lesions were complex
(61.9% B2/C), calciﬁed (25.5%), and containing thrombus (47.4%). Low perfusion
(TIMI 0/1) was observed in 43.8% of lesions before procedure, while after procedure
TIMI 3 was achieved in 96.0%. Most of the STEMIs had anterior (50%) or inferior
(39%) location. 43% of all STEMI patients received adjunctive treatment: either
hemodynamic support (9.0%), intravenous thrombolysis (15.7%), pre-procedural GP
IIB/IIIa inhibitor (9.9%), thrombus aspiration (26.1%) or other speciﬁc treatment
(14.9%). At 1 year, 8 patients died because of cardiac reasons (1.0%), 15 patients
suffered re-infarctions (1.9%) 19 patients underwent TLR (2.4%) and 9 (1.1%)
patients TVR. The TLF rate was 3.4%, while MACE rate was 4.3%. There were 9
(1.1%) deﬁnite or probable stent thromboses, of which 1 acute, 7 subacute and one late
ST. In the patient cohort followed at 3-year, 2 patients died from cardiac causes
(0.8%), 10 had re-infarction (4.0%) with a TLF rate of 6.1%. No patient suffered very
late stent thrombosis between 1- and 3-years follow-up.
Conclusions: Despite limitations of registry and potential bias in enrolling lower risk
patients our data show that treatment of STEMI patients with bioresorbable polymer
coated DES was associated with favorable mid- and long-term outcomes and low rate
of stent thrombosis. Those data, conﬁrm both efﬁcacy and safety of DES with bio-
resorbable polymer in this complex patient's subset.
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Background: The purpose of this observational study was to evaluate the effects of radial
artery access (RA) versus femoral artery access (FA) in octogenarians undergoing percu-
taneous coronary intervention (PCI) due to acute coronary syndrome, i.e. ST-elevation
myocardial infarction (STEMI) and unstable angina/non-STEMI (UA/NSTEMI).
Methods: Data were obtained from the SCAAR registry (Swedish Coronary Angi-
ography and Angioplasty Registry) for PCI procedures performed in Västra Götaland
region in Sweden between 2005-2011. We evaluated 30-days mortality in 1429
elderly patients  80 years of age. PCI was performed through RA in 542 patients and
through FA in 887 patients. The two groups were compared using Cox proportional
hazards regression with shared frailty to account for hierarchical database. Adjust-
ments for the differences in baseline characteristics were made with propensity score.
The following variables were included in the calculation of the propensity score: age,
gender, indication for PCI, smoking habits, hypertension, diabetes, hyperlipidaemia,
severity of coronary disease, previous infarction, previous PCI, previous coronary
artery by-pass surgery (CABG), anticoagulation therapy with glycoprotein IIb/IIIa
receptor antagonists (GP IIb/IIIa), bivalirudin, clopidogrel, unfractionated heparin
/low-molecular weight heparins (UH/LMWH), year, hospital.
Results: The mean age was 83.4  3.2 and 83.5  3.1 in the RA and FA group
respectively (p¼0.51). The two groups were balanced regarding gender, diabetes,acts/ORAL/STEMI and High Risk Patients B15
